Arcutis Biotherapeutics Profit Margin

Arcutis Biotherapeutics (ARQT) currently reports a profit margin of 6.15% as of June 2026. That compares with -35.4% in the prior-year period — up 117.4% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Arcutis Biotherapeutics's profit margin history and peer comparisons.

Arcutis Biotherapeutics's profit margin increased from -35.4% to 6.15% — a 117.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Arcutis Biotherapeutics's profit margin of 6.15% is lower than the Healthcare sector average of 21.34%. That is roughly 71.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Arcutis Biotherapeutics's current 6.15% should be judged against Healthcare norms (sector average: 21.34%) and against ARQT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 6.15%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Arcutis Biotherapeutics, and consider following ARQT for alerts when major investors trade the stock.